MA53920A - Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 - Google Patents

Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Info

Publication number
MA53920A
MA53920A MA053920A MA53920A MA53920A MA 53920 A MA53920 A MA 53920A MA 053920 A MA053920 A MA 053920A MA 53920 A MA53920 A MA 53920A MA 53920 A MA53920 A MA 53920A
Authority
MA
Morocco
Prior art keywords
antibodies
subcutaneous administration
providing subcutaneous
providing
administration
Prior art date
Application number
MA053920A
Other languages
English (en)
Inventor
Kim Anne Campbell
Ivo Nnane
Donald Raible
Cathye Shu
Zhenhua Xu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA53920A publication Critical patent/MA53920A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053920A 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 MA53920A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862747107P 2018-10-17 2018-10-17

Publications (1)

Publication Number Publication Date
MA53920A true MA53920A (fr) 2021-09-15

Family

ID=68531583

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053920A MA53920A (fr) 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Country Status (11)

Country Link
US (1) US20200121588A1 (fr)
EP (1) EP3867275A2 (fr)
JP (1) JP2022512722A (fr)
KR (1) KR20210077725A (fr)
CN (1) CN113195540A (fr)
AU (1) AU2019362868A1 (fr)
BR (1) BR112021007227A2 (fr)
CA (1) CA3116878A1 (fr)
MA (1) MA53920A (fr)
MX (1) MX2021004465A (fr)
WO (1) WO2020081881A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CA2986594C (fr) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anticorps anti-cd38 pour le traitement de l’amyloïdose à chaînes légères et d’autres tumeurs malignes hématologiques positives à cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
CA3204187A1 (fr) * 2021-01-14 2022-07-21 Stefan Steidl Anticorps anti-cd38 et leurs utilisations
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
CA3216410A1 (fr) * 2021-04-21 2022-10-27 Guy Dipierro Methodes de traitement et de dosage de compositions de cellules tueuses naturelles
US20230134748A1 (en) * 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2025160986A1 (fr) * 2024-02-02 2025-08-07 Keymed Biosciences (Chengdu) Co., Ltd. Anticorps monoclonal anti-cd38 et son application

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
EP3312196B1 (fr) 2005-03-23 2019-07-17 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
EP1888647A2 (fr) 2005-05-24 2008-02-20 MorphoSys AG Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
KR20140091038A (ko) * 2011-11-03 2014-07-18 톨러러 세러퓨틱스 인코포레이티드 T-세포 반응의 선택적 억제를 위한 항체 및 방법
CA2909952C (fr) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
KR102630475B1 (ko) * 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 항 인간 ip-10 항체 및 이의 용도
AU2019244478B2 (en) * 2018-03-28 2025-11-06 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies

Also Published As

Publication number Publication date
CN113195540A (zh) 2021-07-30
MX2021004465A (es) 2021-08-24
WO2020081881A3 (fr) 2020-05-22
AU2019362868A1 (en) 2021-05-13
CA3116878A1 (fr) 2020-04-23
US20200121588A1 (en) 2020-04-23
JP2022512722A (ja) 2022-02-07
WO2020081881A2 (fr) 2020-04-23
BR112021007227A2 (pt) 2021-08-10
KR20210077725A (ko) 2021-06-25
EP3867275A2 (fr) 2021-08-25

Similar Documents

Publication Publication Date Title
EP3447137A4 (fr) Préparation d'enzyme liquide et son procédé de préparation
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
MA49394A (fr) Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps
EP3393647A4 (fr) Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles
EP4000601A4 (fr) Préparation d'injection d'ast-3424 stable et procédé de préparation
EP3683205A4 (fr) Procédé de préparation d'isocyanate aliphatique
EP3398939A4 (fr) Dérivé d'acrylanilide, son procédé de préparation et ses applications en pharmacie
EP3516713A4 (fr) Procédé de préparation d'ensembles d'électrodes
EP3927701A4 (fr) Procédé de préparation de diamides anthraniliques et d'intermédiaires correspondants
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3824897A4 (fr) Composition de médicine traditionnelle chinoise et son procédé de préparation et d'application
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP4005561A4 (fr) Préparation nanomicellaire d'icaritine et son procédé de préparation et son application
EP4015519A4 (fr) Procédé de préparation d'asénapine
EP3970744A4 (fr) Injection stable de secukinumab et procédé pour sa préparation
EP3782674A4 (fr) Procédé d'amorçage d'ensemble de perfusion et ensemble de perfusion
EP3432925A4 (fr) Administration d'un anticorps monoclonal anti-lgr5
EP3878435A4 (fr) Préparation de liposomes d'irinotécan, procédé de préparation et application associées
EP3932400A4 (fr) Inhalant de type solution de péramivir et son procédé de préparation
EP3369426A4 (fr) Procédé pour augmenter la production de lymphocytes t cytotoxiques (ctl) spécifiques pour un antigène et d'anticorps
EP3421521A4 (fr) Procédé de préparation d'un dérivé de polyéthylène glycol dialdéhyde
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
EP3903592A4 (fr) Procédé de production d'une poudre granulée et poudre granulée